PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
MGH Thoracic OncologyCongratulations to Dr. @ilennes of @MGHCancerCenter on her study describing the experience of the first 1000+ patients seen in the integrated, multidiscplinary pulmonary nodule program at MGH! #lungcancer #earlydetection
Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC,
including those with CNS metastases and those previously treated with crizotinib.
Because crizotinib-refractory patients have few treatment options, lorlatinib...
The current standard initial therapy for advanced ALK-positive non-small cell lung
cancer (NSCLC) is a second-generation ALK tyrosine kinase inhibitor (TKI) such as
alectinib. The optimal next-line therapy after failure of a second-generation...
MGH Thoracic OncologyCongratulations to Dr. Jessica Lin, Dr. @AdamJSchoenfeld, and Dr. Viola Zhu, et al. on their newest JTO article! This multicenter retrospective analysis evaluated the efficacy of platinum-based chemo in ALK+ NSCLC after progression on second-gen #ALK TKIs.